Kventiax

Quetiapine, the active ingredient in Kventiax, is an atypical antipsychotic presented as an oral tablet for oral use. It treats schizophrenia, bipolar disorder, and serves as adjunctive therapy for major depressive disorder in adult patients. GNH USA supplies Kventiax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quetiapine acts on central nervous system pathways implicated in psychosis and mood regulation. - Schizophrenia: reduces psychotic symptoms and lowers relapse risk. - Bipolar disorder: stabilises mood and diminishes manic episodes. - Major depressive disorder (adjunctive): enhances response to antidepressants in treatment‑resistant depression.

Quetiapine may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Dizziness or light‑headedness - Dry mouth - Constipation - Weight gain - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Neuroleptic malignant syndrome - Severe hypotension or tachycardia - Seizures - Suicidal thoughts or behaviours - Life‑threatening allergic reactions

Before initiating quetiapine, clinicians should consider several safety measures. - Monitor metabolic parameters: regularly assess weight, glucose and lipid levels. - Assess for suicidal ideation: especially during early treatment phases. - Evaluate cardiovascular status: caution in patients prone to orthostatic hypotension. - Use cautiously in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: taper under medical supervision. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Quetiapine interacts with several drug classes and may require dose adjustments.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase quetiapine plasma levels. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation and respiratory depression. - Antihypertensives: may cause excessive orthostatic hypotension.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): heightened risk of serotonin syndrome. - Anticholinergic agents: increased anticholinergic burden. - Alcohol: enhances central nervous system depression.